Global Lewy Body Dementia Treatment Market Projected to Discern Stable Expansion During 2018 to 2026

Posted on 2018-11-21 by Mark Hub in Healthcare // 0 Comments

Fact.MR

Lewy body dementia (LBD), also known as dementia with Lewy bodies, is the second most cause of progressive dementia in the U.S., following Alzheimer’s disease. Lewy body dementia is characterized by progressive decline in mental abilities such as memory, change in alertness and attention. There are two types of Lewy body dementia, viz. dementia with Lewy body and Parkinson’s disease dementia. Lewy body dementia is a progressive disease, i.e., symptoms start to show gradually and worsen with age. Progression of Lewy body dementia differs from person to person depending on age, overall health, extent of symptoms, etc. Common symptoms of Lewy body dementia include visual hallucinations, sleep difficulties, cognitive problems, poor regulation of body function, depression, apathy, etc. Typical chances of survival of patient with Lewy body dementia can be 5-7 years after the onset of symptoms. However, early diagnosis and immediate treatment may lengthen this time to 20 years. Currently, there are no treatments to cure Lewy body dementia and only symptomatic treatments are recommended. Currently available Lewy body dementia treatment may slow down the disease progression. Lewy body dementia treatment involves multidisciplinary action plans, each of which addresses management of different symptoms. For instance, melatonin and other OTC sleeping aids are recommended for treatment of sleeping disorders. Levodopa is prescribed for improvement in motor function. A comprehensive treatment plan may involve medications, physical and other types of therapy, and counseling.

Request Customized Report As Per Your Requirements: https://www.factmr.com/connectus/sample?flag=RM&rep_id=1154

Rapidly growing aging demographics coupled with growing incidence of dementia are the factors driving the growth of Lewy Body Dementia Treatment Market over the forecast period. According to the NHS U.K., over 100,000 people in the U.K are suffering from Lewy body dementia and is one of the common types of dementia. Lewy body dementia accounts for approximately 5–15% of all dementia. Number of patients with comorbid conditions such as LBD and Alzheimer’s disease, LBD and Parkinson’s disease, Senile dementia with LBD, etc. are growing rapidly, which is expected to drive the growth of Lewy body dementia treatment market over the forecast period. However, there exist no differential diagnostic tests that can differentiate LBD from other similar disorders such as Alzheimer’s disease and Parkinson’s disease. This restricts early treatment of Lewy body dementia, which may deter the global market growth.

The global Lewy body dementia treatment market is segmented on the basis of treatment type, distribution channel, and geography:

Segmentation by Treatment Type

Sleep Disorder Treatment
Cognitive Impairment Treatment
Paradoxical Agitation Treatment
Motor Function Improvement Treatment

Segmentation by Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Drug Store

Early and aggressive treatment of cognitive symptoms with anticholinergics is recommended to patients with Lewy body dementia. Treating all sleep disorders is necessary for optimal cognitive function. Melatonin and clonazepam are suggested for treatment of REM sleep behavior disorder. Some medications used to treat Alzheimer’s disease also may be used to treat the cognitive symptoms of LBD. Recently approved Excelon patch by Novartis AG, can be used to treat cognitive symptoms of LBD. By distribution channels, retail pharmacy segment is expected to lead the global market.

Browse full details about Lewy Body Dementia Treatment Market report: https://www.factmr.com/report/1154/lewy-body-dementia-treatment-market

Examples of some of the key players identified in the global Lewy body dementia treatment market are Sun Pharmaceutical Industries Limited, Apotex Corporation, GlaxoSmithKline Plc., Pfizer Inc., Sanofi SA, Boehringer Ingelheim International GmbH, Mallinckrodt, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals, Inc., and Sandoz (Novartis AG), among others.

Regional analysis includes

North America
Latin America
Europe
Asia Pacific
Middle East & Africa

Report Highlights:

Shifting Industry dynamics
In-depth market segmentation
Historical, current and projected industry size Recent industry trends
Key Competition landscape
Strategies for key players and product offerings
Potential and niche segments/regions exhibiting promising growth
A neutral perspective towards market performance

Make an inquiry for purchasing this report: https://www.factmr.com/connectus/sample?flag=AE&rep_id=1154

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Matched content

Editor’s pick